Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Rhinitis
- Rhinoconjunctivitis
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Screening
Participation Requirements
- Age
- Between 14 years and 65 years
- Gender
- Both males and females
Description
Double blind placebo-controlled study. The subjects will receive medication during 4 months.
Double blind placebo-controlled study. The subjects will receive medication during 4 months.
Tracking Information
- NCT #
- NCT02654223
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Javier Subiza, PhD; MD Clinica Subliza Principal Investigator: Carmen Diéguez, PhD; MD Hospital Universitario 12 de Octubre Study Director: Pedro Ojeda, PhD; MD Clínica Ojeda Principal Investigator: Javier Ruiz Hornillos, PhD; MD Hospital Universitario Infanta Elena Principal Investigator: Matilde Domínguez, PhD; MD Hospital Universitario Puerta de Hierro Principal Investigator: Emilio Solano, MD Hospital Universitario Ramón y Cajal Principal Investigator: Antonio Moreno Clínica Atlas Principal Investigator: Pedro Guardia Hospital Universitario Virgen Macarena Principal Investigator: Agustín Orovigt Hospital Viamed Santa Ángela de la Cruz Principal Investigator: Alberto Caso Hospital San Agustín Principal Investigator: Alicia Alonso Clínica Alianza Médica Principal Investigator: Amparo Conde Hospital Nisa Sevilla Aljarafe
Get Well Soon